Navigation Links
Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference
Date:3/22/2011

development while exploring D-tagatose as a potential treatment for high triglycerides, a risk factor for atherosclerosis, myocardial infarction, and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides.  For more information, please visit www.spherix.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Array Architects is proud of a 30-year history ... hospitals and health systems. It is a niche market ... to the advancement of both the healthcare and design ... Laura Silvoy has been chosen to share her healthcare ... , Laura will present her Process Simulation expertise ...
(Date:11/18/2014)... , Nov. 18, 2014  Great Basin Scientific, Inc. ... announced that the management will host a conference call and ... development programs on Thursday, Nov. 20, at 4:30 pm EST ... have made since the Company,s recent IPO and would like ... Basin,s management," said Ryan Ashton , President and Chief ...
(Date:11/17/2014)... N.J. , Nov. 17, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today the formation of ... strategic guidance to the Company as it advances ... hypericin) for the treatment of cutaneous T-cell lymphoma ...
(Date:11/15/2014)... Burlington, MA (PRWEB) November 13, 2014 ... today announced they were named one of the Boston ... among the Medium Sized Businesses in Massachusetts to receive ... Work’ honors employers who take care of their most ... The awards are presented annually, and are based on ...
Breaking Biology Technology:Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2
... Nov. 21 ViroPharma Incorporated,(Nasdaq: VPHM ) ... and chief financial officer of ViroPharma, will present,at ... at 3:30,P.M. ET on Tuesday, November 27, 2007. ... Palace Hotel., ViroPharma also announced that Michel ...
... Sciences,(UK) Ltd "OGeS" announces today that Christopher Hibberd, ... Vice President Corporate,Development at Biosite Incorporated, has joined ... over 15 years of experience in business,strategy and ... as,CEO of Astute Medical, Inc. and prior to ...
... LONDON, Nov. 21 Syngenta and the Royal,Society of ... Network to help promote the economic and social development ... whole continent,is being established initially in Kenya. Its purpose ... them to achieve greater levels of,innovation and scientific development., ...
Cached Biology Technology:ViroPharma to Present at Two Upcoming Healthcare Conferences 2Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors 2Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors 3Syngenta and The Royal Society of Chemistry Launch African Science Initiative 2Syngenta and The Royal Society of Chemistry Launch African Science Initiative 3
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
(Date:11/2/2014)... Physics World , James Dacey explores the ways in ... take their innovations from the lab into the commercial ... all start-up companies as they move from prototype to ... main factors: physics-based inventions are usually far from market-ready ... be a lot more complicated than had been originally ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
... Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University ... Cancer or G-DOC. Under development for two ... normally only available in scattered information libraries and tissue banks, ... new information. G-DOC also contains relevant tools to analyze ...
... For the first time, scientists have discovered that a poorly ... a respiratory virus attack may affect the outcome of the ... , a journal of the American Society for Microbiology. ... manual, its DNA. The best known of these RNAs ...
... Periodontitis, a common inflammatory disease in which gum tissue ... potential bone and tooth loss. Although traditional treatments concentrate ... inflammatory response. In an article in the November issue ... , researchers from Harvard Medical School and Harvard School ...
Cached Biology News:Unique database of cancer -- designed to personalize treatment -- is launched 2Unique database of cancer -- designed to personalize treatment -- is launched 3Unique database of cancer -- designed to personalize treatment -- is launched 4New class of biomolecules triggered in response to respiratory virus infection 2New class of biomolecules triggered in response to respiratory virus infection 3New class of biomolecules triggered in response to respiratory virus infection 4Consuming polyunsaturated fatty acids may lower the incidence of gum disease 2
Agarose Gel Loading Dye Mixture 6X...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: